Foundation Medicine Signs Data Partnership with Cancer Outcomes Tracking and Analysis (COTA, Inc.) to Inform Value-Based Cancer Treatment

Foundation Medicine Partners with EmergingMed to Offer Clinical Trial Navigation Services for Physicians and Patients

First Evaluation of SAGE-547 to Treat Super-Refractory Status Epilepticus in Children Published in Annals of Neurology

Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014

Rhythm Presents Positive Phase 2 Study Results for Relamorelin for Chronic Constipation

Alcresta Presents New Data Demonstrating Potential of Proprietary Enzyme-Based Technology to Improve Nutrition in Patients with Exocrine Pancreatic Insufficiency

Eleven Biotherapeutics Appoints Wendy L. Dixon, PhD to Board of Directors

SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor

Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China

Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin

Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation

Voyager Therapeutics Commemorates Opening of New Headquarters

Foundation Medicine Announces Timing for Third Quarter 2014 Financial Results and Conference Call

Priority Health is First Health Plan to Cover FoundationOne® and FoundationOne® Heme to Enhance Precision Cancer Treatment

Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221

bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy

Blueprint Medicines to Present at JMP Securities Life Sciences Private Company Conference

Constellation meets contractual milestones and receives balance of $15 million loan

Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005

Agios Pharmaceuticals to Webcast R&D Day on October 15, 2014

Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis

Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome

Blueprint Medicines to Present at 13th Annual BIO Investor Forum

Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014

Zafgen Completes Enrollment of Phase 2a Trial of Beloranib in Hypothalamic Injury-Associated Obesity

SAGE Therapeutics to Participate in the 2014 Leerink Partners Rare Disease Roundtable

Zafgen to Present at 2014 Leerink Partners Rare Disease Roundtable

Agios Pharmaceuticals to Present at the 2014 Leerink Partners Rare Disease Roundtable

FierceBiotech names Editas Medicine as one of its Fierce 15 Biotech Companies of 2014

FierceBiotech Names Voyager Therapeutics as one of its “Fierce 15†Biotech Companies of 2014

First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines

Nurix, Inc. Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer

Frances K. Heller Rejoins Zafgen Board of Directors

Sanofi and MyoKardia Announce Groundbreaking Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease

SAGE Therapeutics Appoints Michael F. Cola to the Company\'s Board of Directors

Afferent Pharmaceuticals Names Kathleen Sereda Glaub as Chief Executive Officer

Blueprint Medicines Discovers Novel Cancer Drug Targets

Blueprint Medicines to Participate in Morgan Stanley Global Healthcare Conference 2014

Blueprint Medicines Presents Positive Data on BLU-554 for Hepatocellular Carcinoma

Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer

SAGE Therapeutics Presents New Preclinical Data on SAGE-217 at Eilat Conference on New Anti-Epileptic Drugs

Eleven Biotherapeutics to Participate in Upcoming Investor Conferences in September

Rhythm Files Registration Statement for Proposed Initial Public Offering

SAGE Therapeutics Reports Second Quarter 2014 Financial Results

Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation

Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results

Seventh Sense Biosystems Closes $16 Million Series B Financing

Allergan Acquires LiRIS® Program from TARIS Biomedical®

Zafgen Reports Second Quarter 2014 Financial Results

bluebird bio Reports Fiscal Second Quarter 2014 Financial Results